Zusammengesetzter Bewertungsbereich · konservativ €24–€26 / fair €29–€41 / optimistisch €47–€54. Bei €28.02, Zwischen dem konservativen und dem fairen Bereich.
Bei Veröffentlichung €27.96 (26. Juni 2026)
Parent Carl Zeiss AG plans to buy up to €200m of Carl Zeiss Meditec shares in the market.
Possible impact:May affect free-float supply and perceived parent support, though ZEISS says no delisting or structural measures are planned.
ZEISS Medical Technology signed an agreement with Aier Eye Hospital for 25 VISUMAX 800 femtosecond laser systems.
Possible impact:May support expectations for China and international refractive-surgery equipment demand amid concern over weak China business.
ZEISS announced early clinical implantations of the AT LUCIA toric 721P IOL, with selected European availability expected later in 2026.
Possible impact:May affect cataract and astigmatism product growth expectations, though commercial impact depends on launch timing.
Carl Zeiss Meditec disclosed the appointment of Vitrolife CEO Bronwyn Brophy O’Connor as its new CEO.
Possible impact:May affect expectations for strategic realignment and management stability; the exact start date remains pending.
Carl Zeiss Meditec appointed Vitrolife CEO Bronwyn Brophy O'Connor as its next chief executive.
Possible impact:May affect expectations for leadership stability and restructuring execution.
Automatically summarized from public sources; for context only, not investment advice.
Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.
Noch keine Analysen zu dieser Aktie in Ihrer Sprache.
